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Introduction: The progression of amyotrophic lateral sclerosis (ALS) through the brain has recently been staged using
independent neuropathological and neuroimaging modalities. The two schemes tie into the concept of pathological
spread through corticofugal axonal transmission that stems from observation of oligodendrocyte pTDP-43 aggregates
along with neuronal inclusions. Here, we aimed to assess evidence of transmission along axonal pathways by looking for
pTDP-43 oligodendrocyte pathology in involved white matter tracts, and to present a first validation of the
neuropathological staging scheme.
pTDP-43 immunohistochemistry was performed in select white matter tracts and grey matter regions from the staging
scheme in postmortem-confirmed ALS cases (N = 34). Double-labelling immunofluorescence was performed to confirm
co-localisation of pTDP-43 immunoreactivity to oligodendrocytes.
Results: While pTDP-43 immunoreactive oligodendrocytes were frequent in the white matter under the motor and
sensory cortices, similar assessment of the white matter along the corticospinal tract and in the corpus callosum and
cingulum bundle of the same cases revealed no pTDP-43 pathology, questioning the involvement of oligodendrocytes in
pathological propagation. The assessment of Betz cell loss revealed that the lack of deep white matter pTDP-43
oligodendrocyte pathology was not due to an absence of motor axons. Assessment of the propagation of pathology to
different grey matter regions validated that all cases could be allocated to one of four neuropathological stages, although
Stage 4 cases were found to differ significantly in age of onset (~10 years older) and disease duration
(shorter duration than Stage 3 and similar to Stage 2).
Conclusions: Four stages of ALS neuropathology can be consistently identified, although evidence of sequential clinical
progression requires further assessment. As limited pTDP-43 oligodendrocyte pathology in deep corticospinal and other
white matter tracts from the motor cortex was observed, the propagation of pathology between neurons may not
involve oligodendrocytes and the interpretation of the changes observed on neuroimaging should be modified
accordingly.
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N 5 34 11 14 9
M:F 3:2 21:13 6:5 11:3 4:5
Mean age at death, y
(SD)
67 (10) 64 (8) 65 (10) 62 (9) 66 (7)
Range, y 55-80 47-81 47-81 53-77 57-78
Mean duration, y (SD) - 2 (2) 3 (2) 2 (1) 3 (2)
Range, y - 0.4-7 1-3.6 0.4-6.1 0.6-4.5
Mean PMI, h (SD) 22 (13) 21
(19)
18 (18) 19 (7) 26
(29)
Range, h 12-43 5-99 5-72 7-31 5-99
aNo differences between groups
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Motor neuron disease covers a group of neurodegenera-
tive disorders that affect different parts of the motor
system, be it the upper motor neurons in the primary
motor cortex and brainstem or the lower motor neurons
in the spinal cord. Amyotrophic lateral sclerosis (ALS)
with both upper and lower motor neuron involvement is
the most common presentation, accounting for more
than 75 % of cases with motor neuron disease [1, 2]. The
key histological feature of sporadic ALS is related to the
formation of cytoplasmic inclusions containing phosphory-
lated 43-kDA TAR DNA-binding protein (pTDP-43) [3, 4].
Although the motor system is primarily affected in ALS, a
large body of neuropathological and neuroimaging evidence
suggests that non-motor regions become progressively
involved [5–10].
Recently, Brettschneider and colleagues defined four
neuropathological stages of ALS [6], proposing that
lesions first develop in the motor cortex, brainstem
motor nuclei of cranial nerves V, VII and X-XII, and
spinal cord α-motoneurons in Stage 1. In Stage 2, the
prefrontal cortex, reticular formation, precerebellar nu-
clei and red nucleus are seemingly involved, followed by
further expansion into the prefrontal and postcentral
cortices and striatum by Stage 3. Finally, the pathology is
thought to extend to anteromedial portions of the tem-
poral lobe and eventually affect the hippocampus by
Stage 4. The earliest and most common lesions are
found in oligodendrocytes [6], and in association with
animal studies, it has been proposed that early oligo-
dendrocyte involvement is important for the propagation
of pathology to neurons in ALS [7, 11–14].
The idea of disease propagation from one brain region
to the next has also been reinforced by cell models [15]
and neuroimaging studies [9, 10]. In assessing white mat-
ter tract involvement, Kassubek and colleagues were able
to differentiate ALS patients into four similarly staged
groups [8], with corticospinal tract involvement in Stage 1,
corticorubral and corticopontine involvement in Stage 2,
corticostriatal in Stage 3 and the perforant pathway in-
volved in Stage 4. A positive correlation between these
ALS stages and disease duration was found, with an
average increase in disease duration from 10 months at
Stage 1 to 20 months at Stage 4 in the 88 cases analysed
[8]. While there are limited longitudinal studies [9, 10], it
seems that grey matter is more affected over time com-
pared to the severity and spread of white matter changes
[16], although further longitudinal studies are needed to
validate cross-sectional data concerning potential disease
progression.
While white matter involvement is a prominent feature
in neuroimaging investigations of the ALS brain and
substantiates the idea of spread along these tracts, to our
knowledge no study has tried to verify this concept bylooking for the presence of pathology in the core white
matter regions implicated. The primary objective of this
investigation was to identify pathological evidence of
transmission along axonal pathways by looking for pTDP-
43 oligodendrocyte pathology in regions implicated by
neuroimaging, namely the corticospinal tract in the pos-
terior limb of the internal capsule, the corpus callosum
and the cingulum bundle [8]. We also present the first
independent validation of the neuropathological staging
scheme proposed by Brettschneider and colleagues [6].Material and methods
Cases
ALS cases were collected by the New South Wales Tissue
Resource Centre with approval from the Human Ethics
Committee of the University of Sydney. Inclusion criteria
were neurologically and neuropathologically confirmed
ALS with pTDP-43 pathology [17]. Exclusion criteria were
strong family history of a neurological condition, presence
of co-existing dementia or neuropathology sufficient to
reach criteria for another neurodegenerative disease
[18, 19]. Thirty-four ALS patients met criteria (n = 21
males, n = 13 females, age range = 47-81 years) and were
matched for age and sex to controls with no evidence of a
neurological or neuropathological disease (n = 3 males,
n = 2 females, age range = 55-80 years). ALS cases had
variable deficits at disease onset, including upper limb onset
(n = 11), lower limb onset (n = 14) and bulbar onset (n = 9),
but these subsets did not differ in age at onset, age at death
or disease duration (Table 1). Ten ALS cases had the pres-
ence of a C9ORF72 expansion confirmed on DNA testing
or inferred through staining of dipeptide repeats in the
cerebellum [20]. This study was approved by the Human
Research Ethics Committees of the University of New
South Wales and the University of Sydney.










+ - - - 1 (3 %)
Stage
2
+ + - - 8 (24 %)
Stage
3
+ + + - 16 (47 %)
Stage
4a
+ + + + 9 (26 %)
a Note three cases had pTDP-43 pathology observed in the hippocampus con-
sistent with Stage 4 ALS
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To look for evidence of pathological spread, de-identified
formalin-fixed, paraffin embedded tissue blocks were ob-
tained and sectioned at 10 μm. Fixed brain tissue in 19
cases (56 %) was taken from the hemisphere contralateral
to the side first affected clinically, in 4 cases (12 %) the
sampled region was ipsilateral to the first affected side and
in 11 cases (32 %) laterality of onset was bilateral or
unknown. In all but three cases, validation of grey matter
disease staging was performed using the following recom-
mended blocks [6]: (1) the primary motor cortex with the
underlying white matter (affected in Stage 1), (2) the
medulla oblongata taken at the level of nerve XII contain-
ing the reticular formation and inferior olive (lower motor
neurons affected in Stage 2), (3) the sensory cortex of the
post-central gyrus (affected in Stage 3,), and (4) the hippo-
campal formation (affected in Stage 4). In the event that
no pathology was observed in the sensory cortex for Stage
3, (5) the striatum (caudate nucleus and putamen) was
examined as an alternate region involved in Stage 3 [6].
The following regions implicated in the neuroimaging
literature [8–10] were sampled to assess oligodendroglia
spreading of pathological TDP-43: (A) the corticospinal
tract in the posterior limb of the internal capsule, (B)
corpus callosum sampled at the level of the mammillary
bodies, and (C) cingulum bundle also sampled at the
level of the mammillary bodies. Three adjacent sections
of these regions were cut in five cases with the most
severe pathology in the motor cortex to ensure immuno-
positive oligodendrocytes were not missed due to the
use of 10 μm sections. ALS neuropathology was identi-
fied using immunoperoxidase staining with antibodies to
pTDP-43 (pS409/410, 1:40,000, Cosmo Bio) as well as
native TDP-43 (1:1000, Protein Tech) in a subset of five
cases, both optimised following the manufacturer’s
standard protocol. Antigen retrieval was performed by
boiling for 25 min in 0.01 M sodium citrate buffer solu-
tion (pH 6.0) for the pTDP-43 antibody and Tris EDTA
(pH 9.0) buffer solution for the native TDP-43 antibody.
The primary antibodies were incubated for 48 h at 4 °C
and for 1 h at 37 °C respectively, and visualised using
secondary EnVision Dual Link Polymer (Dako) and DAB
(Sigma-Aldrich), followed by a haematoxylin counterstain.Assessment of ALS neuropathology
Validation of the ALS neuropathological staging scheme
was performed in all but three cases by assessing the
presence (+) or absence (−) of pTDP-43 pathology in the
regions listed above. Based on the regional involvement
outlined in Table 2, each case was assigned to one of the
four neuropathological stages. In the remaining three
cases, pTDP-43 pathology observed in the hippocampus
was consistent with Stage 4 ALS.The severity of Betz cell loss and pTDP-43 pathology
(including neuronal cytoplasmic inclusions, glial cytoplas-
mic inclusions and dystrophic neurites) was also evalu-
ated. For Betz cell loss, the motor cortex from 32 the
cases was assessed in sections taken from 3–5 consecutive
blocks by an experienced neuropathologist, and the num-
ber of healthy-looking, normal-sized Betz cells in the
lower half of the motor strip in each section was graded
from 0 (no Betz cells) to 3 (number of Betz cells typically
seen in a healthy subject). The scores from each section
were averaged to produce a final grade for each case.
For pTDP-43 severity, the densest region of pTDP-43
pathology in the grey and white matter of 31 cases was
independently graded under a 20x objective using a semi-
quantitative scoring system: 0- pathology absent; 1- sparse
pathology with no more than 5 inclusions in the entire
region; 2- mild pathology with on average 1–5 inclusions
in the densest region; 3- moderate pathology with an
average of 6–10 inclusions in the densest region; 4- severe
pathology with an average of 11 or more inclusions in the
densest region (Additional file 1: Figure S1). Assessment
of the inter-rater agreement on the severity of pTDP-43
pathology grading in ten randomly selected cases using κ
statistics revealed near perfect agreement (κ = 0.8) [21].
Assessment of oligodendroglial involvement
Double-labelling immunofluorescence was performed using
antibodies for ALS neuropathology (pTDP-43; 1:10,000)
and oligodendroglia (anti-tubulin polymerisation promoting
protein p25α, Abcam; 1:250) [22] to confirm localisation of
pathology in non-neuronal cells. Antigen retrieval was
performed as outlined above and the primary antibody
cocktail was incubated for 48 h at 4 °C and visualised using
an anti-mouse secondary antibody conjugated to Alexa 594
(1:200) and anti-rabbit secondary antibody conjugated to
Alexa 488 (1:200) (Molecular Probes). Slides were cover-
slipped with ProLong Gold Antifade Reagent with DAPI
(Molecular Probes) and assessed using optional sectioning
with the Apotome.2 on the Zeiss AxioImager.M2. Specifi-
city of immunofluorescence was tested by: 1) excluding one
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was observed) and 2) excluding both primary antibodies
(no immunofluorescence observed). The motor cortex
(highest density of ALS neuropathology) in the six most
severe ALS cases was chosen for evaluation. Ten images of
grey matter and ten images of white matter were taken
at 200x magnification (approximately 8 % of the aver-
age motor strip) and the number of inclusions observed
in neuronal cell bodies (identified by their nucleoli),
oligodendrocytes (identified by p25α immunoreactivity)
or “other” structures were counted and averaged across
all images to produce a representative distribution of
pTDP-43 co-localisation across different cell types.
“Other” structures included pTDP-43 immunoreactivity
in non-p25α-immunoreactive glial cells with an obvious
nucleus, potential p25α immunoreactive pTDP-43 extra-
axonal inclusions (not associated with a nucleus), or
pTDP-43 inclusions detached from any other identifiable
structures, such as dystrophic neurites. Assessment of the
inter-rater agreement in the number of pTDP-43-
immunoreactive oligodendrocyte inclusions in the images
(N = 10 images compared out of 60 available) revealed <8
% difference between two investigators.
Statistics
All statistical analysis was performed using SPSS software
(version 21 for Mac, SPSS Inc., Chicago, IL, USA). Means
and standard deviations are shown. Kruskal-Wallis and
Mann–Whitney U statistics were used to determine differ-
ences between groups and Spearman rank correlations
and χ2 analyses performed to determine relationships
between clinical and pathological variables. p <0.05 was
considered statistically significant.
Results
Pathological evidence of transmission along axonal
pathways
As expected, all ALS cases were immunopositive for
pTDP-43 pathology in one or more of the grey matter
regions examined: i.e. the motor cortex, brainstem,
sensory cortex, striatum and hippocampus (see Fig. 1).
As expected, no pathology was observed in any of the
controls. Surprisingly, assessment of the posterior limb
of the internal capsule, the corpus callosum and the
cingulum bundle revealed no pTDP-43 pathology. Inclu-
sions were absent from sections stained with both the
phosphorylated and native TDP-43 antibodies, even
when serial sections were examined. The only white
matter pTDP-43 observed in the samples was in the
subcortical white matter associated with the motor and
sensory cortices. The pTDP-43 white matter pathology
observed in these regions was largely associated with
oligodendrocytes (see Fig. 1e). The absence of pTDP-43
pathology further along these axonal tracts was anunexpected finding, particularly considering the large
body of evidence to suggest white matter alterations in
these regions [8–10], and also because the selected regions
sampled from the internal capsule, corpus callosum and
cingulum bundle were closely associated with the motor
network. Instead of the expected oligodendroglial transmis-
sion along axonal pathways, the observation of pTDP-43
immunoreactivity in oligodendrocytes close to cortical areas
suggests a more localised mechanism of oligodendroglial
involvement within regions of close proximity.
Grey matter pTDP-43 pathology and validation of the ALS
staging scheme in a representative cohort
In the motor cortex, pTDP-43 immunopositive neuronal
cytoplasmic inclusions (Fig. 1a), glial cytoplasmic inclusions
and dystrophic neurites were identified. In the brainstem,
immunopositive inclusions were mainly skein-like (Fig. 1b)
or dot-like cytoplasmic inclusions in the reticular formation
and/or the inferior olivary nucleus. In some cases, pTDP-
43 pathology was also observed in the XII nerve nucleus.
The pTDP-43 pathology in the sensory cortex was similar
to that of the motor cortex, but with a lesser degree of
severity. In the hippocampus (Fig. 1c), there was marked
involvement of the granule cells of the dentate gyrus, which
in some cases was accompanied by inclusions in neurons of
the CA regions.
The distribution of ALS cases across the neuropatho-
logical stages is outlined in Table 2: one case had Stage 1
(motor cortex pathology only), 8 had Stage 2 (Stage 1 +
brainstem pathology), 16 had Stage 3 (Stage 2 + sensory or
striatal pathology), and 9 had Stage 4 (Stage 3 + hippocam-
pal pathology in 6, and hippocampal pathology in 3). Of
these 34 cases, four had slightly variant distributions of
pTDP-43 pathology: two cases fit the staging scheme only
after review of the striatum as an alternate region to the
sensory cortex, one was included in Stage 2 with pTDP-43
immunopositivity in the brainstem but none in the motor
cortex due to a complete loss of Betz cells in the section
examined, and one was included in Stage 3 with pTDP-43
immunopositivity in the motor and sensory cortices but
none in the brainstem, due to a lack of available tissue at
the appropriate level. Inherently, all of our cases fit the
neuropathological staging scheme suggesting that the
staging scheme can successfully be applied to typical ALS
cohorts and that the ALS cases assessed in this investiga-
tion were comparable with previous studies.
Assessment of motor cortex severity and oligodendroglial
involvement
The severity of Betz cell loss was variable across all stages
and did not influence the severity of pTDP-43 pathology
in the motor cortex. Correlations revealed no relationship
between the loss of Betz cells and disease stage or the se-
verity of pTDP-43 pathology (Additional file 2: Figure S2).
Fig. 1 pTDP-43 pathology in the motor cortex (a), inferior olivary nucleus (b), hippocampal dentate gyrus (c), caudate nucleus (d), and
oligodendrocytes in the white matter underlying the motor cortex (e)
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in the posterior limb of the internal capsule of all cases is
not due to a complete loss of motor neurons from all
cases, and particularly from cases with Stage 4 disease (see
Additional file 2: Figure S2). Furthermore, the density of
oligodendrocytes in ALS did not appear to differ from that
seen in control sections (see Additional file 3: Figure S3)
suggesting a loss of oligodendrocytes does not underlie
the absence of pTDP-43 staining.
The severity of pathology in the motor cortex (Fig. 2a)
and its subcortical white matter (Fig. 2b) was graded semi-
quantitatively, and the distribution of severity grades across
the four stages plotted. Moderate to severe pTDP-43 path-
ology was only observed in Stages 3 and 4. Correlation
analysis showed that the severity of pTDP-43 pathology in
the underlying white matter was linearly associated to that
in the overlying grey matter (Rho = 0.854, p < 0.001) with
the grey matter having more severe pTDP-43 pathology on
average (Fig. 2c). A significant correlation was found
between the severity of pTDP-43 pathology in the white
matter and neuropathological stage (Rho = 0.379, p = 0.035,
Fig. 2d), with Stage 1 included or not in the analysis. In
addition, there was a trend for the severity of pTDP-43
pathology in the grey matter severity to correlate to neuro-
pathological stage (Rho = 0.349 p = 0.055). While the sever-
ity of pTDP-43 pathology in the motor cortex and the
underlying white matter did appear to increase with stage,
the stages themselves did not appear to reflect the same
clinical course of disease for all groups (see below).
For the cases with severe grey matter pathology (n = 6),
double-labelling immunofluorescence was performed to
confirm that the pTDP-43-immunoreactive aggregates
observed in the motor cortex and underlying white matter
were indeed mainly in neurons and oligodendrocytes.
Double labelling with the oligodendrocyte specific p25α
antibody showed pTDP-43-immunoreactive inclusions
either surrounding oligodendroglial nuclei (Fig. 3a-f) or
wrapped around supposed oligodendrocyte-ensheathedaxons (Fig. 3g-i). Neuronal pTDP-43-immunoreactive
inclusions (Fig. 3b arrowhead) were more diffuse, consist-
ent with the pathology observed with pTDP-43 immuno-
peroxidase staining. Quantitation showed that the
majority of inclusions (58 % in the grey matter) were
found in oligodendrocytes (Fig. 4), with a relative absence
of inclusions observed in satellite oligodendrocytes (Add-
itional file 4: Figure S4).
Relationship between pathological staging and clinical
progression
As only one case had Stage 1 disease, this group was
excluded prior to nonparametric analyses. Group analyses
between pathological stages and clinical characteristics for
all other cases are summarised in Table 3. A similar age at
onset might be expected in sporadic ALS cases of different
stages, however only cases in Stages 2 and 3 had a similar
age at disease onset, while cases with Stage 4 presented
approximately 10 years later (Table 3). Progressively
longer disease duration might also be expected if there is
progression from one stage to the next, however, while
Stage 3 had a longer disease duration than Stage 2, Stage 4
did not differ from Stage 2 (Table 3). Since Stages 2 and 3
presented with a similar age at onset, the longer disease
duration in Stage 3 is consistent with these two groups
being on a continuum. Stage 4 however, presented with
later-onset disease and had a shorter disease duration than
Stage 3, suggesting that this group does not lie on the
same continuum and possibly represents a separate ALS
cohort with an altered disease course (Additional file 5:
Figure S5).
Discussion
While conventionally regarded to be a disease that
exclusively targets the motor system network, imaging
and pathological studies have since provided evidence to
suggest that ALS is a multisystem neurodegenerative dis-
order. This can be seen by the presence of characteristic
Fig. 2 The proportion of cases with increasing severity of (a) grey and (b) white matter pTDP-43 pathology across the disease stages, (c) linear
relationship between the severity of pTDP-43 pathology in the grey matter and white matter, and (d) linear relationship between the severity of
pTDP-43 pathology in the white matter and disease stage
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motor system [5–7, 23], and the demonstration of extramo-
tor involvement using neuroimaging techniques [8–10]
The progression of ALS throughout the brain has been
staged using two different modalities- pathological spread
using autopsy samples [6] and spread through white matter
tracts using diffusion tensor imaging [8]. Currently, the
concept of disease progression in ALS involves a theory of
corticofugal axonal spread, suggesting that grey matter
regions become sequentially involved through the white
matter tracts that connect them [7].
In this study, grey matter immunostaining revealed
cytoplasmic pTDP-43 inclusions in the neurons and glia
of the motor cortex, brainstem, sensory cortex, striatum
and hippocampus confirming previous studies reporting
deposits in areas within and outside the motor system
[5–7, 23] and independently validating the ALS neuro-
pathological staging scheme recently proposed by Brettsch-
neider and colleagues [6]. Corresponding white matter
immunostaining revealed glial pTDP-43-immunoreactive
pathology immediately under the motor and sensorycortices. Double-labeling immunofluorescence confirmed
that glial pathology observed in both grey and white matter
was co-localised in oligodendrocytes. Thus our cases appear
to be consistent with those reported in the literature.
In the present study we sought evidence for transmis-
sion along axonal pathways by looking for similar pTDP-
43 oligodendrocyte pathology in the posterior limb of the
internal capsule, the corpus callosum and the cingulum
bundle. Alterations to diffusion parameters are believed to
reflect pathophysiological damage to axons and myelin
[24, 25], suggesting inclusions in oligodendrocytes might
be found along these tracts. Contrary to this, p-TDP-43
immunostaining revealed no such evidence. This was an
unexpected result given the prominence of these white
matter tracts in ALS diffusion imaging. For instance,
reductions in fractional anisotropy and changes to mean
diffusivity present as consistent findings in the internal
capsule [8–10], with changes more pronounced in the
posterior limb through which fibres descend from the
direct corticospinal tract [26]. The corpus callosum and
cingulum bundle have similarly been identified as involved
Fig. 3 Co-localisation of pTDP-43 pathologies (red) in oligodendrocytes (green) and neurons (arrowhead) in the motor cortex (a-c) and the
underlying white matter (d-i)
Fig. 4 Distribution of grey and white matter pathology in the motor
cortex. Phosphorylated TDP-43 inclusions were observed in either
neurons, oligodendrocytes or “other” non-p25α immunoreactive glial
cells with an obvious nucleus, potential p25α immunoreactive pTDP-43
extra-axonal inclusions (not associated with a nucleus), or pTDP-43
inclusions detached from any other identifiable structures, such as
dystrophic neurites
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ALS and in those with little clinical upper motor neuron
involvement [8–10]. A pathological study has shown that
30 % of 27 ALS cases had white matter pTDP-43-
immunoreactivity under the cingulate cortex (median
severity score of 0.4 on a scale of 0 (none) to 3 (severe))
[23] and so a lack of pTDP-43 pathology in the cingulum
bundle in the present study was unexpected, especially
considering its connection to areas reportedly involved by
end stage disease [6, 7]. In the motor region, the severity
of white matter pTDP-43 pathology linearly associated
with the severity of pathology in the grey matter, consist-
ent with similar data from the spinal cord [14] where the
severity of pTDP-43 pathology and neuronal loss corre-
lated closely with grey and white matter oligodendrocyte
involvement, and to the onset of disease in the spinal cord.
Spinal cord oligodendrocyte involvement was reported to
occur in areas otherwise void of pTDP-43 aggregates and
neuronal loss, suggesting that grey matter oligodendroglial
involvement represents an early event in the disease
process [14].
Our data revealed oligodendrocyte pTDP-43 pathology
close to involved cortical areas and not further along
axonal tracts, suggesting a more localised mechanism of
Table 3 Relationship between pathological staging and clinical
progression
Stage 2 Stage 3 Stage 4 p-value
Gender (M:F) 5:3 10:6 6:3 0.628a
Mean age at onset (SD) 60 (9) 58 (6) 70 (8)* 0.007b
Mean age at death (SD) 61 (9) 61 (6) 71 (8)* 0.017b
Mean duration since diagnosis (SD) 1.5 (0.7) 3.5 (1.7)* 1.4 (0.6) 0.002b
Bulbar onset (N) 3 4 2 0.904a
Upper limb onset (N) 2 6 3
Lower limb onset (N) 3 6 4
shading indicates p < 0.05
aχ2 analysis
bKruskall Wallis test
*significantly different group using posthoc Mann–Whitney U test
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aggregates remain limited to the lower motor neurons of
the brainstem and spinal cord [6, 7, 14]. An assessment
of Betz cells revealed no relationship between the num-
ber of surviving Betz cells and the grey matter severity
score, confirming that the lack of deep white matter
pTDP-43 pathology in regions such as the posterior limb
of the internal capsule was not due to the loss of upper
motor neurons and degeneration of their axons. Given
that healthy Betz cells require support from functional
oligodendrocytes, it is further unlikely that the lack of
oligodendrocytic pathology was due to a loss of oligo-
dendroglia, a suggestion supported by our finding of a
similar density of oligodendrocytes in white matter tracts
of ALS and controls (Additional file 3: Figure S3).
Our data provide some evidence that the early patho-
logical stages of ALS may be on a continuum based on
their mean age at onset and increasing disease duration
(Additional file 5: Figure S5). However, the ALS cases with
the greatest spread of pathology (Stage 4) were significantly
older at onset and had short disease duration, suggesting a
difference between this group and other disease stages.
Further exploration of these findings is warranted, espe-
cially in ALS cases with co-existing dementia as such cases
were excluded from this study.
Conclusions
The present study validates the neuropathological staging
scheme and confirms that regional assessment of pTDP-
43 pathology allows for the identification of four specific
stages as described previously [6]. Our data offer support
to the suggestion that Stages 2 and 3 sit on a continuum,
while Stage 4 may represent an alternate phenotype as this
group is significantly older at onset and has a shorter
disease duration. Despite a predominance of oligodendro-
glial pTDP pathology in the grey matter regions affected
and evidence of affected Betz cell in many cases, no case
had observable pTDP-43 oligodendrocyte pathology in
remote but connected white matter tracts. Consideringthe careful selection of these tracts from neuroimaging
evidence of the progression of ALS pathology along them,
the lack of pTDP-43 pathology in deep white matter tracts
questions the concept that pTDP-43 pathology underlies
these neuroimaging changes. Further clarification is re-
quired to determine the cellular correlates of the white
matter changes identified in ALS, as involvement of these
tracts is not related to significant pTDP-43 pathology.
Additional files
Additional file 1: Figure S1. Examples of the semi-quantitative scoring
for pTDP-43 immunoperoxidase pathology in the motor cortex (A-D) and
underlying white matter (E-G): sparse in cortex (A) and white matter (E); mild
in cortex (B) and white matter (F); moderate in cortex (C) and white matter
(G); severe in cortex (D). Double labelling immunofluorescence confirmed
that most white matter inclusions were localised in oligodendrocytes (H).
Scale bar in G applies to all figures. (PNG 2663 kb)
Additional file 2: Figure S2. Absence of any relationship between Betz
cell numbers and either disease stage (A) or the severity of grey matter
pTDP-43 pathology (B) (EPS 732 kb)
Additional file 3: Figure S3. There was no obvious difference in the
density of oligodendrocytes in sections of the posterior limb of the
internal capsule (A), the corpus callosum (B, C) or the cingulum (D, E)
between controls (B, D) and ALS cases (A, C, E) Scale in E applies to B-D.
(TIFF 4930 kb)
Additional file 4: Figure S4. Assessment of affected neurons in the
motor cortex revealed limited oligodendrocytic pTDP-43 pathology in
satellite oligodendrocytes (C, arrowheads), even when neurons contained
pTDP-43 immunorectivity (A-C). Pathologically affected oligodendrocytes
were generally at some distance from affected neurons (D), Scale bar in B
applies to C and D. (TIFF 9184 kb)
Additional file 5: Figure S5. Stylised differences in age at onset and
disease duration between the neuropathological stages in the cohort
suggests that Stage 4 does not lie on the same continuum as Stages 2
and 3 (PNG 6 kb)
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